Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
03/21 GILEAD SCIENCES : British Columbia lists EPCLUSA™ on public drug plan to t..
03/20 GILEAD SCIENCES : EPCLUSA™, to treat all six genotypes of chronic hepatiti..
03/14 GILEAD SCIENCES, INC. : ex-dividend day
03/09 GILEAD SCIENCES : to Present at the Barclays Global Healthcare Conference on Tue..
03/09 GILEAD SCIENCES : Reports on Medicinal Chemistry Findings from Gilead Sciences P..
03/07 Drugmaker shares slip as Trump tweets about pricing system
03/02 GILEAD SCIENCES : New Findings from Gilead Sciences Yields New Data on B-Cell Ly..
02/28 GILEAD SCIENCES : to Present at the Barclays Global Healthcare Conference on Tue..
02/27 GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
02/24 GILEAD SCIENCES : Announces Findings from New Preclinical Study Evaluating Novel..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/25 MARKETPLACE ROUNDTABLE : Biotech Hanging In The Balance
03/24 JEROME DODSON AND THE PARNASSUS FUND : Why Are They So Successful? It's Simple
03/23 11 Trades That Profited In 3 Weeks At Seeking Alpha - 4 Are Still In Play!
03/23 Gilead Doesn't Offer A Compelling Risk/Reward
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
Advertisement
Financials ($)
Sales 2017 24 635 M
EBIT 2017 15 210 M
Net income 2017 10 403 M
Debt 2017 978 M
Yield 2017 3,17%
P/E ratio 2017 9,20
P/E ratio 2018 9,98
EV / Sales 2017 3,62x
EV / Sales 2018 3,94x
Capitalization 88 240 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 81,5 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-5.73%88 240
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
VERTEX PHARMACEUTICALS..22.14%22 354
More Results